← All trials
NCT05216484
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 18, 2022
- Primary completion
- Oct 30, 2022
- Completion date
- Dec 30, 2022
- First posted
- Jan 31, 2022
- Last posted
- May 23, 2022
- Enrollment
- 480
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Government of ChinaCollaborator
- Government of ChinaOverall official - principal investigator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.